Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 6,080 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

NCT04801043
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107, Imipenem/Cilastatin, placebo
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 30, 2026, 12:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

NCT02111096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2409021, Sitagliptin, Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
26
States / cities
Concord, California • Fresno, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

NCT01583374
View directory record Official record
Conditions
Ankylosing Spondyloarthritis
Interventions
Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
20
States / cities
Peoria, Arizona • La Jolla, California • Palm Desert, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans

NCT01865123
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Transcendental Meditation, Prolonged Exposure, Educational control
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of a New Drug Treatment for Acne

NCT01326780
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screening and Management of Unhealthy Alcohol Use in Primary Care

NCT04248023
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Abuse, Alcohol Use Disorder
Interventions
Practice Facilitation
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
13,680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 12:26 PM EDT
Terminated No phase listed Observational

A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

NCT02370823
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Regenexx SD
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
35 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

NCT03500679
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Wichita, Kansas • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

NCT00955279
View directory record Official record
Conditions
Sarcoidosis
Interventions
Placebo, Golimumab, Ustekinumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

NCT03392896
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
DCR-PHXC, Placebo
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Withdrawn Not applicable Interventional

Health-eBrain Study

NCT02903862
View directory record Official record
Conditions
Depression and Burden in Caregivers
Interventions
Mindoula, DANA
Behavioral · Device
Lead sponsor
AnthroTronix, Inc.
Industry
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigation of the Gut Microbiome and Statin Response

NCT04098003
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
Sony Tuteja
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phildelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple Dose Study of LY3023703 in Healthy Participants

NCT01849055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 12:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Almond on Facial Skin Collagen and Wrinkles

NCT06074276
View directory record Official record
Conditions
Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin
Interventions
Food: whole almonds, Food: non-nut snack
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 30, 2026, 12:26 PM EDT
Active, not recruiting Phase 2 Interventional

Ibudilast for Treating Alcohol Use Disorder

NCT05414240
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcoholism
Interventions
Ibudilast, Medical management, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Lebrikizumab, Pirfenidone, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 30, 2026, 12:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Microarchitecture in Women With and Without Fracture

NCT01049191
View directory record Official record
Conditions
Osteoporosis, Fracture
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

NCT06064006
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0487-0111, Placebo (NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

NCT02961218
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
8 Years to 20 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

NCT04442490
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
39
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 30, 2026, 12:26 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 12:26 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 30, 2026, 12:26 PM EDT